Table 1.
Patient and treatment characteristics
| Factor | No. (79) | % | |
|---|---|---|---|
| Sex | Male | 48 | 61 |
| Female | 31 | 39 | |
| Median age, years (range) | 60 (21-93) | ||
| Cancer type | Lung cancer | 45 | 57 |
| Melanoma | 15 | 19 | |
| Other | 19 | 24 | |
| Treatment timing | Within 1 month (concurrent) | 35 | 44 |
| 1-6 months (sequential) | 44 | 56 | |
| First treatment | Radiation therapy | 36 | 46 |
| Immunotherapy | 43 | 54 | |
| Immunotherapy category | Anti-PD-1 | 48 | 61 |
| Anti-PD-L1 | 14 | 18 | |
| Anti-CTLA-4 | 12 | 15 | |
| Anti-PD-1/PD-L1+anti-CTLA-4 | 5 | 6 | |
| Laterality irradiated lesion | Right lung | 40 | 51 |
| Left lung | 27 | 34 | |
| Mediastinum | 12 | 15 | |
| Site irradiated lesion | Mediastinum | 32 | 41 |
| Hilum | 19 | 24 | |
| Upper lobe | 14 | 18 | |
| Lower lobe | 14 | 18 | |
| Fractionation | Palliative | 46 | 58 |
| Stereotactic body radiation therapy | 18 | 23 | |
| Other | 15 | 19 | |
| Median radiation therapy dose, cGy (range) | 3000 (1800-7400) | ||
| Median follow-up time, months (range) | 4.5 (0.2-55.6) | ||
| Median follow-up time for survivors, months (range) | 5.9 (2.4-55.6) | ||
CTLA-4, cytotoxic T-lymphocyte-associated protein 4; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1.